Johnson & Johnson (JNJ) News
Filter JNJ News Items
JNJ News Results
|Loading, please wait...|
JNJ News Highlights
- JNJ's 30 day story count now stands at 77.
- Over the past 25 days, the trend for JNJ's stories per day has been choppy and unclear. It has oscillated between 2 and 21.
- INS, AGE and SAFE are the most mentioned tickers in articles about JNJ.
Latest JNJ News From Around the Web
Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.
Johnson & Johnson (JNJ) revealed that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has given its green light to a booster dose of the company's COVID-19 vaccine for individuals above 18 years of age. The company said that the request for emergency use authorization was approved with a unanimous vote of 19-0. The dose is supposed to be administered at least two months after the initial vaccination.
Mr. Wonderful is calling for a Bitcoin boom. But he hasn't forgotten about dividends.
The S&P and Nasdaq closed higher on Monday with the biggest boosts from the highest-profile technology and communications companies while investors eyed product news from Apple Inc and appeared optimistic about the third-quarter earnings season. After a weak start following disappointing economic data from China, the S&P and Nasdaq gathered steam in late morning with gains in FAANG stocks - Facebook Inc, Apple, Amazon.com Inc, Netflix Inc, Alphabet Inc's Google - as well as Microsoft Corp.
U.S. stocks rose on Monday on gains in heavyweight technology companies, although sentiment remained fragile due to slowing economic growth in China and concerns of elevated inflation due to a relentless surge in oil prices. Eight of the 11 major S&P 500 sectors rose, led by consumer discretionary and followed by energy, which tracked Brent crude oil to its highest since October 2018.
U.S. may soon authorize boosters for all 3 in-use vaccines, as experts renew plea for unvaccinated to get their shots
A Food and Drug Administration advisory committee voted unanimously Friday that allowing adults who were initially vaccinated with the Johnson & Johnson one-dose vaccine against COVID-19 to get a booster is safe and effective, freeing the way for the agency to authorize its use.
Stocks wavered on Monday ahead of a busy week of earnings, including reports from Tesla Inc (NASDAQ:TSLA) and Netflix Inc (NASDAQ:NFLX). Investors were skittish about slowing economic growth in China, the world’s second largest economy, and concerns about rising oil prices affecting prices across the spectrum. China reported the slowest pace of economic growth in a year in the third quarter, hurt by power shortages and the struggling property sector.
The idea is to offer additional flexibility so that Americans in certain situations can receive booster doses of a different vaccine than they received for their initial dose.
The company is honored to be recognized for its leadership in helping shape the trajectory of healthcare around the world.
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
After a strong trading week last week, the Dow is down -190 points, the S&P 500 is -25 and the Nasdaq -75 points.